Viewing data from:

YOSPRALA

NDA

ASPIRIN; OMEPRAZOLE | N205103 | GENUS LIFE SCIENCES INC

2 strengths2 unique patents0 unique exclusivities

Patent Timeline

2 unique patents by expiration date

Active (2)Today

2027

2028

2029

2030

2031

2032

2033

Today

Mar. 13, 2033

Jan. 2, 2033

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Aralez Pharmaceuticals Inc. et al v. Teva Pharmaceuticals USA, Inc. et al 2:2017cv00071 4 patentsANDA 209791aspirin and omeprazole	E.D. Tex.	2017-01-23	Terminated 2017-10-30	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

8 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 81MG;40MG

RLD

2 patents0 exclusivities▴

TABLET, DELAYED RELEASE;ORAL | Approved: Sep 14, 2016

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
9539214	Mar 13, 2033	—	—	—		—
9987231	Jan 2, 2033	—	—	—		—

#002 — 325MG;40MG

RLD

2 patents0 exclusivities▾

TABLET, DELAYED RELEASE;ORAL | Approved: Sep 14, 2016